According to a new study, 34 percent of metastatic melanoma patients who received the immunotherapy drug, Opdivo, have survived. This rate is in comparison to other treatments generating only a 16.6 percent survival rate between 2005 and 2011. These immunotherapy treatments effectively double the survival rate of the disease and represent the first long-term follow-up of survival data from trials using the anti-PD-1 immunotherapy drug, which prevents the immune system’s T-cells from attacking cancer. Click here to learn more.
Last Updated on May 8, 2020 by Aimed Alliance
